Edmond DE Rothschild Holding S.A. increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 3.1% during the first quarter, Holdings Channel reports. The firm owned 252,154 shares of the biopharmaceutical company’s stock after buying an additional 7,551 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Bristol-Myers Squibb were worth $13,713,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares during the period. Welch Investments LLC boosted its stake in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the period. Crestwood Advisors Group LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter worth approximately $116,000. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 60 shares during the period. Hedge funds and other institutional investors own 69.79% of the company’s stock.

Bristol-Myers Squibb Company (BMY) traded down 0.7402% on Thursday, reaching $56.9751. The company’s stock had a trading volume of 1,191,949 shares. The company has a market capitalization of $93.43 billion, a price-to-earnings ratio of 20.8090 and a beta of 1.17. The stock has a 50 day moving average price of $55.81 and a 200-day moving average price of $54.58. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $61.30.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.69 EPS. Equities analysts predict that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/edmond-de-rothschild-holding-s-a-has-13-71-million-position-in-bristol-myers-squibb-company-bmy/1470721.html.

A number of equities research analysts have commented on BMY shares. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 target price on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $59.88 price objective on the stock. in a report on Monday, April 24th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday. Finally, Cowen and Company set a $65.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $62.67.

In other news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.23% of the stock is owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.